Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Sci Rep ; 12(1): 3049, 2022 02 23.
Article in English | MEDLINE | ID: mdl-35197552

ABSTRACT

Astrocytes utilize both glycolytic and mitochondrial pathways to power cellular processes that are vital to maintaining normal CNS functions. These cells also mount inflammatory and acute phase reactive programs in response to diverse stimuli. While the metabolic functions of astrocytes under homeostatic conditions are well-studied, the role of cellular bioenergetics in astrocyte reactivity is poorly understood. Teriflunomide exerts immunomodulatory effects in diseases such as multiple sclerosis by metabolically reprogramming lymphocytes and myeloid cells. We hypothesized that teriflunomide would constrain astrocytic inflammatory responses. Purified murine astrocytes were grown under serum-free conditions to prevent acquisition of a spontaneous reactive state. Stimulation with TNFα activated NFκB and increased secretion of Lcn2. TNFα stimulation increased basal respiration, maximal respiration, and ATP production in astrocytes, as assessed by oxygen consumption rate. TNFα also increased glycolytic reserve and glycolytic capacity of astrocytes but did not change the basal glycolytic rate, as assessed by measuring the extracellular acidification rate. TNFα specifically increased mitochondrial ATP production and secretion of Lcn2 required ATP generated by oxidative phosphorylation. Inhibition of dihydroorotate dehydrogenase via teriflunomide transiently increased both oxidative phosphorylation and glycolysis in quiescent astrocytes, but only the increased glycolytic ATP production was sustained over time, resulting in a bias away from mitochondrial ATP production even at doses down to 1 µM. Preconditioning with teriflunomide prevented the TNFα-induced skew toward oxidative phosphorylation, reduced mitochondrial ATP production, and reduced astrocytic inflammatory responses, suggesting that this drug may limit neuroinflammation by acting as a metabolomodulator.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Astrocytes/metabolism , Crotonates/pharmacology , Hydroxybutyrates/pharmacology , Inflammation/metabolism , Nitriles/pharmacology , Toluidines/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Adenosine Triphosphate/metabolism , Animals , Animals, Newborn , Astrocytes/cytology , Astrocytes/drug effects , Cells, Cultured , Chemokines/metabolism , Energy Metabolism/drug effects , Glycolysis/drug effects , Lipocalin-2/metabolism , Mice, Inbred C57BL , Mitochondria/drug effects , Oxidation-Reduction/drug effects , Oxidative Phosphorylation/drug effects , Tumor Necrosis Factor-alpha/metabolism
3.
Aging (Albany NY) ; 12(14): 15134-15156, 2020 07 08.
Article in English | MEDLINE | ID: mdl-32640422

ABSTRACT

Multiple sclerosis (MS) is a central nervous system inflammatory demyelinating disease and the most common cause of non-traumatic disability in young adults. Despite progress in the treatment of the active relapsing disease, therapeutic options targeting irreversible progressive decline remain limited. Studies using skin fibroblasts derived from patients with neurodegenerative disorders demonstrate that cell stress pathways and bioenergetics are altered when compared to healthy individuals. However, findings in MS skin fibroblasts are limited. Here, we collected skin fibroblasts from 24 healthy control individuals, 30 patients with MS, and ten with amyotrophic lateral sclerosis (ALS) to investigate altered cell stress profiles. We observed endoplasmic reticulum swelling in MS skin fibroblasts, and increased gene expression of cell stress markers including BIP, ATF4, CHOP, GRP94, P53, and P21. When challenged against hydrogen peroxide, MS skin fibroblasts had reduced resiliency compared to ALS and controls. Mitochondrial and glycolytic functions were perturbed in MS skin fibroblasts while exhibiting a significant increase in lactate production over ALS and controls. Our results suggest that MS skin fibroblasts have an underlying stress phenotype, which may be disease specific. Interrogating MS skin fibroblasts may provide patient specific molecular insights and aid in prognosis, diagnosis, and therapeutic testing enhancing individualized medicine.


Subject(s)
Activating Transcription Factor 4/metabolism , Amyotrophic Lateral Sclerosis , Endoplasmic Reticulum , Fibroblasts/metabolism , Membrane Glycoproteins/metabolism , Multiple Sclerosis , Transcription Factor CHOP/metabolism , Amyotrophic Lateral Sclerosis/metabolism , Amyotrophic Lateral Sclerosis/pathology , Biological Variation, Population , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/pathology , Energy Metabolism/physiology , Female , Gene Expression Profiling , Humans , Male , Middle Aged , Mitochondrial Diseases/metabolism , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology , Precision Medicine , Skin/pathology
4.
Elife ; 82019 11 04.
Article in English | MEDLINE | ID: mdl-31682229

ABSTRACT

Alexander disease (AxD) is a fatal neurodegenerative disorder caused by mutations in glial fibrillary acidic protein (GFAP), which supports the structural integrity of astrocytes. Over 70 GFAP missense mutations cause AxD, but the mechanism linking different mutations to disease-relevant phenotypes remains unknown. We used AxD patient brain tissue and induced pluripotent stem cell (iPSC)-derived astrocytes to investigate the hypothesis that AxD-causing mutations perturb key post-translational modifications (PTMs) on GFAP. Our findings reveal selective phosphorylation of GFAP-Ser13 in patients who died young, independently of the mutation they carried. AxD iPSC-astrocytes accumulated pSer13-GFAP in cytoplasmic aggregates within deep nuclear invaginations, resembling the hallmark Rosenthal fibers observed in vivo. Ser13 phosphorylation facilitated GFAP aggregation and was associated with increased GFAP proteolysis by caspase-6. Furthermore, caspase-6 was selectively expressed in young AxD patients, and correlated with the presence of cleaved GFAP. We reveal a novel PTM signature linking different GFAP mutations in infantile AxD.


Subject(s)
Alexander Disease/metabolism , Biomarkers/metabolism , Caspases/metabolism , Glial Fibrillary Acidic Protein/metabolism , Adult , Alexander Disease/diagnosis , Alexander Disease/genetics , Astrocytes/metabolism , Binding Sites/genetics , Brain/metabolism , Brain/pathology , Cell Line , Glial Fibrillary Acidic Protein/genetics , Humans , Induced Pluripotent Stem Cells/metabolism , Infant , Intermediate Filaments/metabolism , Mutation , Phosphorylation , Proteolysis , Severity of Illness Index
5.
JCI Insight ; 4(18)2019 09 19.
Article in English | MEDLINE | ID: mdl-31534057

ABSTRACT

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. As insulin resistance impairs mitochondrial oxidative metabolism and increases ROS in skeletal muscle, we considered whether similar events occur in the brain, which - like muscle - is rich in insulin receptors and mitochondria. We show that high-fat diet-induced (HFD-induced) brain insulin resistance in mice decreased mitochondrial ATP production rate and oxidative enzyme activities in brain regions rich in insulin receptors. HFD increased ROS emission and reduced antioxidant enzyme activities, with the concurrent accumulation of oxidatively damaged mitochondrial proteins and increased mitochondrial fission. Improvement of insulin sensitivity by both aerobic exercise and metformin ameliorated HFD-induced abnormalities. Moreover, insulin-induced enhancement of ATP production in primary cortical neurons and astrocytes was counteracted by the insulin receptor antagonist S961, demonstrating a direct effect of insulin resistance on brain mitochondria. Further, intranasal S961 administration prevented exercise-induced improvements in ATP production and ROS emission during HFD, supporting that exercise enhances brain mitochondrial function by improving insulin action. These results support that insulin sensitizing by exercise and metformin restores brain mitochondrial function in insulin-resistant states.


Subject(s)
Cerebral Cortex/drug effects , Insulin Resistance/physiology , Insulin/metabolism , Metformin/administration & dosage , Mitochondria/drug effects , Physical Conditioning, Animal/physiology , Receptor, Insulin/metabolism , Administration, Intranasal , Administration, Oral , Animals , Astrocytes/cytology , Astrocytes/drug effects , Astrocytes/pathology , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/pathology , Diet, High-Fat/adverse effects , Disease Models, Animal , Glucose/metabolism , Humans , Mice , Mitochondria/metabolism , Mitochondria/pathology , Mitochondrial Dynamics/drug effects , Neurons/cytology , Neurons/drug effects , Neurons/pathology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Peptides/administration & dosage , Primary Cell Culture , Receptor, Insulin/antagonists & inhibitors , Sedentary Behavior
6.
FASEB J ; 32(5): 2841-2854, 2018 05.
Article in English | MEDLINE | ID: mdl-29401610

ABSTRACT

Vimentin is a cytoskeletal intermediate filament protein that is expressed in mesenchymal cells and cancer cells during the epithelial-mesenchymal transition. The goal of this study was to identify vimentin-targeting small molecules by using the Tocriscreen library of 1120 biochemically active compounds. We monitored vimentin filament reorganization and bundling in adrenal carcinoma SW13 vimentin-positive (SW13-vim+) cells via indirect immunofluorescence. The screen identified 18 pharmacologically diverse hits that included 2 statins-simvastatin and mevastatin. Simvastatin induced vimentin reorganization within 15-30 min and significant perinuclear bundling within 60 min (IC50 = 6.7 nM). Early filament reorganization coincided with increased vimentin solubility. Mevastatin produced similar effects at >1 µM, whereas the structurally related pravastatin and lovastatin did not affect vimentin. In vitro vimentin filament assembly assays revealed a direct targeting mechanism, as determined biochemically and by electron microscopy. In SW13-vim+ cells, simvastatin, but not pravastatin, reduced total cell numbers (IC50 = 48.1 nM) and promoted apoptosis after 24 h. In contrast, SW13-vim- cell viability was unaffected by simvastatin, unless vimentin was ectopically expressed. Simvastatin similarly targeted vimentin filaments and induced cell death in MDA-MB-231 (vim+), but lacked effect in MCF7 (vim-) breast cancer cells. In conclusion, this study identified vimentin as a direct molecular target that mediates simvastatin-induced cell death in 2 different cancer cell lines.-Trogden, K. P., Battaglia, R. A., Kabiraj, P., Madden, V. J., Herrmann, H., Snider, N. T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells.


Subject(s)
Adrenal Gland Neoplasms/drug therapy , Neoplasm Proteins/metabolism , Simvastatin/pharmacology , Vimentin/metabolism , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/ultrastructure , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Breast Neoplasms/ultrastructure , Cell Death , Female , Humans , Lovastatin/analogs & derivatives , Lovastatin/pharmacology , MCF-7 Cells , Microscopy, Fluorescence , Neoplasm Proteins/antagonists & inhibitors , Vimentin/antagonists & inhibitors
7.
J Vis Exp ; (123)2017 05 18.
Article in English | MEDLINE | ID: mdl-28570536

ABSTRACT

Intermediate filaments (IFs), together with actin filaments and microtubules, form the cytoskeleton - a critical structural element of every cell. Normal functioning IFs provide cells with mechanical and stress resilience, while a dysfunctional IF cytoskeleton compromises cellular health and has been associated with many human diseases. Post-translational modifications (PTMs) critically regulate IF dynamics in response to physiological changes and under stress conditions. Therefore, the ability to monitor changes in the PTM signature of IFs can contribute to a better functional understanding, and ultimately conditioning, of the IF system as a stress responder during cellular injury. However, the large number of IF proteins, which are encoded by over 70 individual genes and expressed in a tissue-dependent manner, is a major challenge in sorting out the relative importance of different PTMs. To that end, methods that enable monitoring of PTMs on IF proteins on an organism-wide level, rather than for isolated members of the family, can accelerate research progress in this area. Here, we present biochemical methods for the isolation of the total, detergent-soluble, and detergent-resistant fraction of IF proteins from 9 different mouse tissues (brain, heart, lung, liver, small intestine, large intestine, pancreas, kidney, and spleen). We further demonstrate an optimized protocol for rapid isolation of IF proteins by using lysing matrix and automated homogenization of different mouse tissues. The automated protocol is useful for profiling IFs in experiments with high sample volume (such as in disease models involving multiple animals and experimental groups). The resulting samples can be utilized for various downstream analyses, including mass spectrometry-based PTM profiling. Utilizing these methods, we provide new data to show that IF proteins in different mouse tissues (brain and liver) undergo parallel changes with respect to their expression levels and PTMs during aging.


Subject(s)
Aging/metabolism , Intermediate Filament Proteins/metabolism , Protein Processing, Post-Translational , Animals , Brain/metabolism , Female , Humans , Liver/metabolism , Male , Mice , Mice, Inbred CBA , Organ Specificity
8.
ACS Chem Neurosci ; 7(11): 1519-1530, 2016 11 16.
Article in English | MEDLINE | ID: mdl-27635664

ABSTRACT

Amyloid beta (Aß) aggregation is generally associated with Alzheimer's onset. Here, we demonstrate that incubation of dopaminergic SH-SY5Y cells with an Aß peptide fragment (an 11-mer composed of residues 25-35; Aß (25-35)) results in elevated intracellular nitrosative stress and induces chemical mutation of protein disulfide isomerase (PDI), an endoplasmic reticulum-resident oxidoreductase chaperone. Furthermore, Aß (25-35) provokes aggregation of both the minor and major biomarkers of Parkinson's disease, namely, synphilin-1 and α-synuclein, respectively. Importantly, fluorescence studies demonstrate that Aß (25-35) triggers colocalization of these Parkinsonian biomarkers to form Lewy-body-like aggregates, a key and irreversible milestone in the neurometabolic cascade leading to Parkinson's disease. In addition, fluorescence assays also reveal direct, aggregation-seeding interactions between Aß (25-35), PDI and α-synuclein, suggesting neuronal pathogenesis occurs via prion-type cross-transfectivity. These data indicate that the introduction of an Alzheimer's-associated biomarker in dopaminergic cells is proliferative, with the percolative effect exercised via dual, independent, Parkinson-pathogenic pathways, one stress-derived and the other prion-like. The results define a novel molecular roadmap for Parkinsonian transfectivity via an Alzheimeric burden and reveal the involvement of PDI in amyloid beta induced Parkinson's.


Subject(s)
Amyloid beta-Peptides/toxicity , Carrier Proteins/metabolism , Dopaminergic Neurons/metabolism , Nerve Tissue Proteins/metabolism , Parkinsonian Disorders/metabolism , Peptide Fragments/toxicity , Protein Aggregation, Pathological , alpha-Synuclein/metabolism , Animals , Apoptosis/physiology , Biomarkers/metabolism , Carrier Proteins/genetics , Cell Line, Tumor , Cytosol/metabolism , Cytosol/pathology , Dopaminergic Neurons/pathology , Dynamic Light Scattering , Flow Cytometry , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Immunohistochemistry , Immunoprecipitation , Intracellular Signaling Peptides and Proteins , Lewy Bodies/metabolism , Lewy Bodies/pathology , Mice , Microscopy, Confocal , Nerve Tissue Proteins/genetics , Parkinsonian Disorders/pathology , Reactive Oxygen Species/metabolism , Transfection , alpha-Synuclein/genetics
9.
Protein J ; 34(5): 349-58, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26385697

ABSTRACT

Endoplasmic reticulum (ER) proteins including protein disulfide isomerase (PDI) are playing crucial roles in maintaining appropriate protein folding. Under nitrosative stress, an excess of nitric oxide (NO) radical species induced the S-nitrosylation of PDI cysteines which eliminate its isomerase and oxidoreductase capabilities. In addition, the S-nitrosylation-PDI complex is the cause of aggregation especially of the α-synuclein (α-syn) protein (accumulation of Lewy-body aggregates). We recently identified a potent antioxidant small molecule, Ferrostatin-1 (Fer-1), that was able to inhibit a non-apoptotic cell death named ferroptosis. Ferroptosis cell death involved the generation of oxidative stress particularly lipid peroxide. In this work, we reported the neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells (SH-SY5Y). We first synthesized the Fer-1 and confirmed that it is not toxic toward the SH-SY5Y cells at concentrations up to 12.5 µM. Second, we showed that Fer-1 compound quenched the commercially available stable radical, the 2,2-diphenyl-1-picrylhydrazyl (DPPH), in non-cellular assay at 82 %. Third, Fer-1 inhibited the ROS/RNS generated under rotenone insult in SH-SY5Y cells. Fourth, we revealed the effective role of Fer-1 in ER stress mediated activation of apoptotic pathway. Finally, we reported that Fer-1 mitigated rotenone-induced α-syn aggregation.


Subject(s)
Cyclohexylamines/pharmacology , Dopamine/metabolism , Neuroblastoma/metabolism , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Phenylenediamines/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Endoplasmic Reticulum Stress/drug effects , Humans , Neuroblastoma/physiopathology , Neurons/cytology , Nitric Oxide/metabolism , Reactive Oxygen Species/metabolism , Rotenone/toxicity
10.
ACS Chem Neurosci ; 5(12): 1209-20, 2014 Dec 17.
Article in English | MEDLINE | ID: mdl-25247703

ABSTRACT

Nitrosative stress mediated S-nitrosylation (SNO) of protein disulfide isomerase (PDI), a housekeeping oxidoreductase, has been implicated in the pathogenesis of sporadic Parkinson's (PD) and Alzheimer's (AD) diseases. Previous cell line studies have indicated that SNO-PDI formation provokes synphilin-1 aggregation, the minor Parkinsonian biomarker protein. Yet no work exists investigating whether SNO-PDI induces α-synuclein aggregation, the major Lewy body constituent associated with Parkinson's pathogenesis. Here, we report that SNO-PDI formation is linked to the aggregation of α-synuclein and also provokes α-synuclein:synphilin-1 deposits (Lewy-body-like debris) normally found in the PD brain. Furthermore, we have examined the ability of a small molecule, 2,3,7,8-tetrahydroxy-chromeno[5,4,3-cde]chromene-5,10-dione (ellagic acid; EA) to scavenge NOx radicals and to protect cells from SNO-PDI formation via rotenone insult both, cell-based and cell-independent in vitro experiments. Furthermore, EA not only mitigates nitrosative-stress-induced aggregation of synphilin-1 but also α-synuclein and α-synuclein:synphilin-1 composites (Lewy-like neurites) in PC12 cells. Mechanistic analyses of the neuroprotective phenomena revealed that EA lowered rotenone-instigated reactive oxygen species (ROS) and reactive nitrogen species (RNS) in PC12 cells, imparted antiapoptotic tributes, and directly interfered with SNO-PDI formation. Lastly, we demonstrate that EA can bind human serum albumin (HSA). These results collectively indicate that small molecules can provide a therapeutic foothold for overcoming Parkinson's through a prophylactic approach.


Subject(s)
Ellagic Acid/pharmacology , Gene Expression Regulation/drug effects , Protein Disulfide-Isomerases/metabolism , Reactive Nitrogen Species/metabolism , Animals , Carrier Proteins/metabolism , Cell Nucleolus/drug effects , Cell Nucleolus/metabolism , Endoplasmic Reticulum Stress/drug effects , HSP70 Heat-Shock Proteins/metabolism , Humans , Nerve Tissue Proteins/metabolism , Nitric Oxide/metabolism , PC12 Cells , Parkinsonian Disorders/blood , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Protein Binding/drug effects , Rats , Reactive Oxygen Species/metabolism , Rotenone/pharmacology , alpha-Synuclein/metabolism
11.
Cell Biol Int ; 38(4): 511-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24375813

ABSTRACT

Protein disulfide isomerase (PDI), an important endoplasmic reticulum-resident oxidoreductase chaperone can bind to estrogens as well as intact with its receptor proteins [i.e. estrogen receptors (ER) α and ß]. It has been postulated that PDI also acts as an intracellular 17ß-estradiol (E2)-binding protein that transports and accumulates E2 in live cells. Drop in E2 level promotes dissociation of E2 from PDI and released in cytosol; the released E2 can augment estrogen receptor-mediated transcriptional activity and mitogenic action in cultured cells by modulating the ERß/ERα ratio. In this study, we observed rotenone-induced damage to PDI leads to significant increase in ERß/ERα ratio by down-regulating ERα and up-regulating ERß. We demonstrated that nitrosative stress induced disruption of the cellular estrogenic status can be prevented through diphenyl difluoroketone (EF24, curcumin analog) intervention by protecting PDI from reactive oxygen species (ROS)-induced damage. Together, our study suggests that both PDI and EF24 can play a vital role in maintaining cellular estrogenic homeostasis.


Subject(s)
Benzylidene Compounds/pharmacology , Estradiol/metabolism , Piperidones/pharmacology , Protein Disulfide-Isomerases/antagonists & inhibitors , Rotenone/toxicity , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Down-Regulation/drug effects , Estrogen Receptor alpha/analysis , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/metabolism , Female , HEK293 Cells , HeLa Cells , Humans , MCF-7 Cells , Microscopy, Confocal , Oxidative Stress/drug effects , Protein Disulfide-Isomerases/analysis , Protein Disulfide-Isomerases/metabolism , Reactive Oxygen Species/metabolism , Up-Regulation/drug effects
12.
Biochem Biophys Res Commun ; 426(3): 438-44, 2012 Sep 28.
Article in English | MEDLINE | ID: mdl-22974977

ABSTRACT

Mitochondrial dysfunction, leading to elevated levels of reactive oxygen species, is associated with the pathogenesis of neurodegenerative disorders. Rotenone, a mitochondrial stressor induces caspase-9 and caspase-3 activation leading proteolytic cleavage of substrate nuclear poly(ADP-ribose) polymerase (PARP). PARP cleavage is directly related to apoptotic cell death. In this study, we have monitored the aggregation of green-fluorescent protein (GFP)-tagged synphilin-1, as a rotenone-induced Parkinsonia-onset biomarker. We report that the innate ketone body, Na-D-ß-hydroxybutyrate (NaßHB) reduces markedly the incidence of synphilin-1 aggregation. Furthermore, our data reveal that the metabolic byproduct also prevents rotenone-induced caspase-activated apoptotic cell death in dopaminergic SH-SY5Y cells. Together, these results suggest that NaßHB is neuroprotective; it attenuates effects originating from mitochondrial insult and can serve as a scaffold for the design and development of sporadic neuropathies.


Subject(s)
3-Hydroxybutyric Acid/pharmacology , Apoptosis/drug effects , Carrier Proteins/metabolism , Dopaminergic Neurons/drug effects , Nerve Tissue Proteins/metabolism , Neuroprotective Agents/pharmacology , Nitrates/metabolism , Oxidative Stress/drug effects , Carrier Proteins/analysis , Caspases/metabolism , Cell Line, Tumor , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , Green Fluorescent Proteins/analysis , Green Fluorescent Proteins/metabolism , Humans , Mitochondrial Diseases/metabolism , Necrosis , Nerve Tissue Proteins/analysis , Nitrosation , Parkinson Disease/metabolism , Protein Folding/drug effects , Rotenone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...